Probiotic to enhance an individual's skin microbiome
Compositions, systems and methods of improving the health of the microbiome of an individual's skin relate to the provision of skin contacting formulations containing beneficial bacteria, postbiotics, metabolites and other microbe components to foster the growth and maintenance of a healthy skin microbiome. One embodiment includes a topical application of Lactobacillus Crispatus to ameliorate skin barrier damage and inflammation using unique combinations of probiotics, prebiotics, postbiotics, and other skin-beneficial ingredients, effectively treating inflammatory skin diseases, such as atopic dermatitis, psoriasis and acne, through the production of tryptophan metabolites that act as AHR agonists.
1. A method of reducing the likelihood of a skin condition that causes skin inflammation in an individual human being, said method comprising:
administering to a region of an individual's skin a therapeutically effective amount of a bacterial formulation comprising at least one bacteria selected from the group consisting of Lactobacillus reuteri, Lactobacillus johnsonii, and Lactobacillus crispatus, Cutibacterium acnes , and Nitrosomonas eutropha , said bacterial formulation comprising a lotion, ointment or gel adapted to be rubbed onto a region of the individual's skin, and abiotic augmentations comprising fatty acids, and wherein said at least one bacteria comprises a heat-killed bacteria.
2. The method as set forth in claim 1 , wherein the bacterial formulation further comprises Janthinobacterium.
3. The method as set forth in claim 1 , wherein the bacterial formulation is in an amount effective to treat, inhibit or reduce the skin condition, wherein the skin condition is selected from the group consisting of eczema, atopic dermatitis, acne, allergic inflammation, ultra-violet-induced skin damage, and skin hypersensitivity.
4. The method as set forth in claim 1 , further comprising administering to the individual a prebiotic, a metabolite, and a postbiotic; a cleanser composition comprising at least one of sodium methyl cocoyl taurate, sodium cocoyl glutamate, coco glucoside, caprylyl/capryl glucoside, sodium cocoyl Isethionate, and cetearyl alcohol; a serum composition comprising at least two of the following: indole-3-carbinol, resveratrol, niacinamide, nicotinic acid, nicotinamide mononucleotide, nicotinamide riboside, quercetin, tryptophan, diiodomethane, Boswellia serrata, and indirubin; and at least one barrier-restoring oil comprising at least one of sunflower oil, coconut oil, murumuru oil, sea buckthorn oil, sachi inchi oil, and babbasu oil.
5. The method as set forth in claim 1 , wherein at least some bacteria in the bacterial formulation have been modified by using a using a clustered regularly interspaced short palindromic repeats (CRISPR) CRISPR associated protein (Cas) system or a CRISPR from Prevotella and Francisella 1(Cpf1) system to reduce the production of a virulence factor by at least one of said live bacteria in said bacterial formulation.
6. The method as set forth in claim 1 , wherein the bacteria is Cutibacterium acnes.
7. The method as set forth in claim 1 , wherein the bacteria in the bacterial formulation produce short-chain fatty acids selected from the group consisting of propionate, acetate, butyrate and valerate.
8. The method as set forth in claim 1 , wherein the bacteria in the bacterial formulation does at least one of: suppress the growth of S. aureus ; reduce the colonization of S. aureus on the individual's skin; and inhibit biofilm formation by S. epidermidis.
9. The method as set forth in claim 1 , further comprising killing or retarding the growth of a pathogenic bacteria within the individual, said pathogenic bacteria selected from the group consisting of Staphylococcus aureus; Pseudomonas aeruginosa; Klebsiella; Streptoccocus; Salmonella; Shigella; Mycobacterium tuberculosis; Enterococcus; E coli; Clostridium; Neisseria gonorrhoeae; Acinetobacter baumannii ; and Campylobacter.
10. The method as set forth in claim 1 , wherein said method further comprises enhancing the growth of a beneficial bacteria in the individual selected from the group consisting of C. acnes, Akkermansia, Bacteroides, Bifidobacterium, Fusobacterium, Coprococcus, Lactobacillus, Propionibacterium, Ruminococcus, Veillonella, Prevotella , and Streptococcus bacteria.
11. The method as set forth in claim 1 , further comprising administering at least two probiotic strains to the individual's skin in a concentration of at least 1×108 via AFU, said at least two probiotic strains being either live or heat-killed and selected from the group consisting of Cutibacterium, Staphylococcus, Corynebacterium, Actinobacteria, Proteobacteria, and Firmicutes.
12. The method as set forth in claim 1 , further comprising administering to the individual's skin at least one probiotic strain that does not upregulate innate immune response genes selected from the group consisting of CXCL1, CXCL3, CXCL8, CXCL10.
13. The method as set forth in claim 1 , further comprising administering to the individual's skin at least one probiotic strain that does not upregulate innate immune response genes selected from the group consisting of IL10RA, PTGS2, F2RL1, TRIM29, TRAF4, LGALS3, CD55, TRIM8, CASP4, IFNGR1, ADA, NOD1, NOS2, and APP.
14. A method of reducing the likelihood of a skin condition that causes skin inflammation in an individual human being, said method comprising:
administering to a region of an individual's skin a therapeutically effective amount of a bacterial formulation comprising L. crispatus , and at least two bacteria selected from the group consisting of L. reuteri, L. johnsonii, Cutibacterium acnes, Janthinobacterium and Nitrosomonas eutropha , said bacterial formulation comprising a lotion, ointment or gel adapted to be rubbed onto a region of the individual's skin, and abiotic augmentations comprising fatty acids, wherein the at least two bacteria comprise heat-killed bacteria and wherein the skin condition is selected from the group consisting of eczema, atopic dermatitis, acne, allergic inflammation, ultra-violet-induced skin damage, and skin hypersensitivity.
15. The method as set forth in claim 14 , wherein the bacterial formulation is in an amount effective to treat, inhibit or reduce a symptom of a disease, disorder, or condition, wherein the disease, disorder, or condition is atopic dermatitis.
16. The method as set forth in claim 14 further comprising a prebiotic, metabolite, postbiotic.
17. The method as set forth in claim 14 , wherein said bacterial formulation further comprises bacteria selected from the group consisting of Faecalibacterium prausnitzii, Bifidobacterium, Lachnospira, Veillonella, Coprococcus, Akkermansia muciniphila and Rothia.
18. A method of reducing the likelihood of a skin condition that causes skin inflammation in an individual human being, said method comprising: topically administering to a region of an individual's skin a therapeutically effective amount of a bacterial formulation comprising heat-killed L crispatus bacteria, said bacterial formulation comprising a lotion, ointment or gel adapted to be rubbed onto a region of the individual's skin, and wherein the bacterial formulation further comprises Janthinobacterium.
19. The method as set forth in claim 18 , further comprising administering to the skin an extract derived from a helminth selected from the group consisting of Capillaria hepatica, Dicrocoelium dendriticum, Ascaris lumbricoides, Enterobius vermicularis, Trichuris trichiura, Ancylostoma duodenale, Necator americanus, Strongyloides stercoralis, Haemonchus contortus , and Trichinella spiralis.
20. The method as set forth in claim 18 , wherein the bacterial formulation is administered to an individual's skin in an amount sufficient for the bacterial formulation to generate an amount of tryptophan metabolites sufficient to act as aryl hydrocarbon receptor (AHR) agonists to thereby reduce inflammation on the individual's skin, wherein the skin condition is selected from the group consisting of eczema, atopic dermatitis, acne, allergic inflammation, ultra-violet-induced skin damage, and skin hypersensitivity.